Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...
The FDA has expanded the approval of Evkeeza® (evinacumab-dgnb) to include children aged 1 year and older with homozygous familial hypercholesterolemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback